--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-24-001640" form_type: "8-K" ticker: "LAB" cik: "0001162194" company_name: "STANDARD BIOTOOLS INC." filed_at: "2024-01-05T23:59:59+00:00" generated_at: "2026-06-07T02:56:46.069943+00:00" event_type: "m_and_a" sentiment: "positive" materiality_score: 0.85 calibrated_materiality_score: 0.85 confidence: "high" source: SEC EDGAR --- # Standard BioTools completes merger with SomaLogic; creates diversified life sciences tools leader ## Summary - Merger closed Jan 5; each SomaLogic share converted to 1.11 shares of LAB common stock. - Combined company has over $500M cash; expects $80M annual cost synergies by 2026. - Board adds SomaLogic directors Tom Carey (Chairman), Troy Cox, Kathy Hibbs; three directors resigned. - Stockholders approved all proposals, including charter amendment raising authorized shares to 600M. ## SEC filing metadata - accession: 0001104659-24-001640 - form_type: 8-K - ticker: LAB - cik: 0001162194 - company_name: STANDARD BIOTOOLS INC. - filed_at: 2024-01-05T23:59:59+00:00 - event_type: m_and_a - sentiment: positive - materiality_score: 0.85 - calibrated_materiality_score: 0.85 - confidence: high - sec_items: 2.01, 5.02, 5.07, 5.03, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/0001104659-24-001640-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/tm2333984d3_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-24-001640 - JSON: https://secwatch.observer/filing/0001104659-24-001640.json - Plain text: https://secwatch.observer/filing/0001104659-24-001640.txt ## Key facts - Executive change Carlos Paya resigned as Director at STANDARD BIOTOOLS INC.. - Action: resigned - Role: Director source text: Carlos Paya, M.D., Ph.D., Laura Clague and Martin Madaus, Ph.D. resigned from Standard BioTools’ board of directors evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/0001104659-24-001640-index.htm - Executive change Martin Madaus resigned as Director at STANDARD BIOTOOLS INC.. - Action: resigned - Role: Director source text: Carlos Paya, M.D., Ph.D., Laura Clague and Martin Madaus, Ph.D. resigned from Standard BioTools’ board of directors evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/0001104659-24-001640-index.htm - Executive change Laura Clague resigned as Director at STANDARD BIOTOOLS INC.. - Action: resigned - Role: Director source text: Carlos Paya, M.D., Ph.D., Laura Clague and Martin Madaus, Ph.D. resigned from Standard BioTools’ board of directors evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/0001104659-24-001640-index.htm - Governance Changes STANDARD BIOTOOLS INC.: Increased authorized common stock from 400,000,000 shares to 600,000,000 shares (effective 2024-01-04). - Change: charter amendment - Effective: 2024-01-04 source text: On January 4, 2024, the Company filed a Certificate of Amendment to its Eighth Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to increase the total number of shares of Standard BioTools Common Stock authorized for issuance thereunder from 400,000,000 shares to 600,000,000 shares (the “Charter Amendment”). evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/0001104659-24-001640-index.htm - M&A Transactions STANDARD BIOTOOLS INC. completed an acquisition involving SomaLogic, Inc. for 1.11 shares of Standard BioTools common stock per share (closed 2024-01-05). - Action: acquisition - Counterparty: SomaLogic, Inc. - Consideration: 1.11 shares of Standard BioTools common stock per share - Closing: 2024-01-05 source text: of the Merger, each issued and outstanding share of common stock of SomaLogic, par value $0.0001 per share (“SomaLogic Common Stock”), was converted into the right to receive 1.11 (the “Exchange Ratio”) shares of common stock of Standard BioTools, par value $0.001 per share (“Standard BioTools Common Stock”), and cash in lieu of fractional shares. evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/0001104659-24-001640-index.htm - Shareholder Votes STANDARD BIOTOOLS INC. shareholders approved To approve the issuance of shares of Standard BioTools Common Stock in connection with the Merger and in accordance with Nasdaq Listing Rule 5635(a) (the 'Standard BioTools Share Issuance Proposal'). at the 2024-01-04 meeting. - Proposal: merger approval - Outcome: passed - Meeting: 2024-01-04 source text: Proposal 1. To approve the issuance of shares of Standard BioTools Common Stock in connection with the Merger and in accordance with Nasdaq Listing Rule 5635(a) (the “Standard BioTools Share Issuance Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 125,739,416 5,186,617 127,586 None evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/0001104659-24-001640-index.htm - Shareholder Votes STANDARD BIOTOOLS INC. shareholders approved To approve the Charter Amendment (the 'Standard BioTools Charter Amendment Proposal'). at the 2024-01-04 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2024-01-04 source text: Proposal 2. To approve the Charter Amendment (the “Standard BioTools Charter Amendment Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 125,698,245 5,230,711 124,663 None evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/0001104659-24-001640-index.htm - Shareholder Votes STANDARD BIOTOOLS INC. shareholders approved To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools’ named executive officers and to SomaLogic’s Chief Executive Officer that is based on or otherwise relates to the Merger. at the 2024-01-04 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2024-01-04 source text: Proposal 3. To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools’ named executive officers and to SomaLogic’s Chief Executive Officer that is based on or otherwise relates to the Merger. Votes For Votes Against Abstentions Broker Non-Votes 119,441,699 11,267,991 343,929 None evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/0001104659-24-001640-index.htm - Shareholder Votes STANDARD BIOTOOLS INC. shareholders approved To approve the A&R 2011 Plan Amendment. at the 2024-01-04 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2024-01-04 source text: Proposal 4. To approve the A&R 2011 Plan Amendment. Votes For Votes Against Abstentions Broker Non-Votes 119,362,194 11,536,749 154,676 None evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/0001104659-24-001640-index.htm - Shareholder Votes STANDARD BIOTOOLS INC. shareholders approved To approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Standard BioTools Share Issuance Proposal and the Standard BioTools Charter Amendment Proposal if there are insufficient votes at the time of such adjournment at the 2024-01-04 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2024-01-04 source text: Proposal 5. To approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Standard BioTools Share Issuance Proposal and the Standard BioTools Charter Amendment Proposal if there are insufficient votes at the time of such adjournment to approve such proposals. Votes For Votes Against Abstentions Broker Non-Votes 124,087,718 6,753,379 212,522 None evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/0001104659-24-001640-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.